Pfizer-BioNTech. COVID-19 vaccines

09/02/2021 Epidemiology

General Data
Name: BNT162b2
Manufacturer Laboratory: Pfizer, Inc., and BioNTech
Type: mRNA * To learn more about the type of vaccines, check our blog “And do, the war has begun. COVID-19 vaccines ”.
Dosage: 2 doses with a difference in the time of application of 21 days.
Ingredients: mRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3- phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.
Injection site: Intramuscular in the arm.
Recommended age: 16 years old and up.
It is not recommended to apply if:
1. You have had severe allergic reactions to ingredients in the vaccine.
2. Reacted severely after receiving the first dose of the vaccine, in which case you should not go to the second dose.
3. Please consider in the two previous cases, allergic reactions to polyethylene glycol (PEG) and polysorbate. Polysorbate is an ingredient that is not included in any of the COVID-19 mRNA vaccines but is closely related to PEG, which is included in vaccines. People who are allergic to PEG or polysorbate should not receive the mRNA vaccine against COVID-19.
Immediate Allergic Reactions:

EXPECTED SYMPTOMS

In the injection arm:

In the body in general:

USEFUL ADVICE

In the injection arm:

In the body in general:

Special considerations: Check with your doctor before applying the vaccine if you meet any of the following points:
1. You have allergies, specify which ones.
2. Have fever.
3. You have a blood disorder (such as Hemophilia) or if you are taking anticoagulants.
4. You have a condition that compromises your immune system (eg Lupus) or you take medications that affect your immune system.
5. You are pregnant or plan to become pregnant.
6. You are breastfeeding.
7. You were inoculated with another COVID-19 vaccine.
Safety
1. According to accumulated studies from clinical trials, people who received this vaccine commonly had mild to moderate reactions after application in a range no greater than 7 days.
2. Fever, tiredness, chills, and headache were common symptoms when receiving the second dose of the vaccine.
Effectiveness: In clinical trials, it recorded a 95% efficacy for the prevention of COVID-19 cases, laboratory data from people with no evidence of previous infections.

References

Like it? Share it!